Abstract
Loxo Oncology, which is owned by Eli Lilly and Company, is partnering with Kumquat Biosciences to develop small-molecule immunotherapies. Lilly will pay Kumquat $70 million up front, with up to $2 billion in milestone payments. Kumquat will use its small-molecule-developing technology to identify potential antitumor candidates, and Lilly will further develop what it deems the most promising.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
